Komrokji, Rami S. http://orcid.org/0000-0002-1876-5269
Singh, Avani M. http://orcid.org/0000-0001-7494-2090
Ali, Najla Al
Chan, Onyee http://orcid.org/0000-0003-2872-1961
Padron, Eric http://orcid.org/0000-0002-4707-7916
Sweet, Kendra
Kuykendall, Andrew
Lancet, Jeffrey E. http://orcid.org/0000-0002-7751-7310
Sallman, David A. http://orcid.org/0000-0003-0504-8233
Article History
Received: 2 August 2022
Revised: 13 October 2022
Accepted: 19 October 2022
First Online: 4 November 2022
Competing interests
: <b>RSK:</b><i>Geron:</i> Consultancy; <i>BMSCelgene:</i> Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; <i>PharmaEssentia:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Jazz:</i> Consultancy, Speakers Bureau; <i>Acceleron:</i> Consultancy; <i>AbbVie:</i> Consultancy; <i>Novartis:</i> Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; <i>Taiho Oncology:</i> Membership on an entity’s Board of Directors or advisory committees. <b>AK:</b><i>BluePrint Medicines:</i> Honoraria, Research Funding, Speakers Bureau; <i>Celgene/BMS:</i> Honoraria, Research Funding, Speakers Bureau; <i>CTI Biopharma:</i> Honoraria; <i>Incyte:</i> Consultancy; <i>Novartis:</i> Honoraria, Speakers Bureau; <i>PharmaEssentia:</i> Honoraria; <i>Abbvie:</i> Honoraria; <i>Prelude:</i> Research Funding; <i>Protagonist:</i> Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding. <b>KS:</b><i>Bristol Meyers Squibb:</i> Honoraria, Membership on an entity’s Board of Directors or advisory committees; <i>Astellas:</i> Consultancy, Membership on an entity’s Board of Directors or advisory committees; <i>AROG:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Novartis:</i> Honoraria, Membership on an entity’s Board of Directors or advisory committees; <i>Gilead:</i> Membership on an entity’s Board of Directors or advisory committees. <b>EP:</b><i>Stemline:</i> Honoraria; <i>Taiho:</i> Honoraria; <i>Blueprint:</i> Honoraria; <i>Incyte:</i> Research Funding; <i>Kura:</i> Research Funding; <i>BMS:</i> Research Funding. <b>JEL:</b><i>Millenium Pharma/Takeda:</i> Consultancy; <i>Celgene/BMS:</i> Consultancy; <i>BerGenBio:</i> Consultancy; <i>Daiichi Sankyo:</i> Consultancy; <i>ElevateBio Management:</i> Consultancy; <i>Agios:</i> Consultancy; <i>Astellas:</i> Consultancy; <i>Jazz:</i> Consultancy; <i>AbbVie:</i> Consultancy. <b>DAS:</b><i>Bristol-Myers Squibb:</i> Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; <i>AbbVie:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Takeda:</i> Consultancy; <i>Aprea:</i> Membership on an entity’s Board of Directors or advisory committees, Research Funding; <i>Agios:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Syndax:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Shattuck Labs:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Novartis:</i> Consultancy, Membership on an entity’s Board of Directors or advisory committees; <i>Magenta:</i> Consultancy; <i>Kite:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Intellia:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Incyte:</i> Speakers Bureau.